Research Article

Protocatechualdehyde Inhibits the Osteoclast Differentiation of RAW264.7 and BMM Cells by Regulating NF-κB and MAPK Activity

Yunyun Qu,1,2 Xin Liu,1 Shuai Zong,1 Huanxin Sun,1 Shuang Liu,1 and Yueran Zhao1

1Department of Central Lab, Shandong Provincial Hospital, Cheeulo College of Medicine, Shandong University, Jinan, Shandong 250021, China
2The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China

Correspondence should be addressed to Yueran Zhao; yrzhao@sdu.edu.cn

Received 11 April 2021; Accepted 7 June 2021; Published 16 July 2021

Academic Editor: Min Tang

Copyright © 2021 Yunyun Qu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Protocatechualdehyde (PCA), an important component of Salvia miltiorrhiza, has many activities, such as anti-inflammatory and antisepsis activities. However, the role of PCA in osteoclasts is not clear. We used RAW264.7 cells (a mouse leukemic monocyte/macrophage cell line) and bone marrow macrophages (BMMs) to probe the role of PCA in osteoclasts and the underlying mechanism. The effects of PCA on cell activity were evaluated with CCK-8 assays. TRAP staining detected mature osteoclasts. Corning Osteo Assay Surface plates were used to examine absorption. The levels of RNA and protein were analyzed, respectively, using RT-PCR and Western blotting. PCA (5 μg/ml) was not toxic to the two cell types but reduced the formation of osteoclasts and bone absorption. Furthermore, PCA restrained the expression of mRNAs encoding proteins associated with osteoclasts and reduced the phosphorylation of proteins in important signaling pathways. The results indicate that PCA inhibits osteoclast differentiation by suppressing NF-κB and MAPK activity.

1. Introduction

Osteoporosis is a degenerative disease with an increasing risk due to aging and is one of the most common diseases in older men [1]. The disease can occur at any age but mainly occurs in elderly men. Approximately 200 million people suffer from osteoporosis worldwide, and this condition has become the seventh most common disease in the world.

Under normal circumstances, bone tissue maintains normal function by constantly updating metabolism. Due to abnormal metabolism, older patients experience bone loss. The increased activity of osteoclasts increases the loss of bone mass, and the attenuated function of osteoblasts decreases the formation of bone mass, leading to fractures in the bone microstructure and a negative balance in bone reconstruction [2]. Therefore, more bone loss than supplementation is the cytological basis for the occurrence of osteoporosis.

Currently, bisphosphonates are common agents used to treat osteoporosis and significantly inhibit the activity of osteoclasts. They have been recommended by many authoritative institutions worldwide due to their clear efficacy [3]. However, the safety of long-term bisphosphonate use has gradually become a concern. Long-term application of bisphosphonates was reported to cause mandibular osteonecrosis, atypical subtrochanteric or femoral shaft fracture, and other adverse reactions [4].

Salvia miltiorrhiza (SM) is a Chinese herbal medicine that has long been used to treat osteoporosis. Clinical trials have shown that SM alone is as effective as traditional drugs in the treatment of osteoporosis and has the advantage of being nontoxic [5]. In vitro experiments have confirmed that SM exerts a good protective effect on ovariectomy-induced osteoporosis and diabetic osteoporosis [6, 7]. Salvianolic acid B is a water-soluble extract of SM. It exerts a protective effect...
on prednisone-induced osteoporosis [8], increasing bone cancellation, improving the bone trabecular structure, and increasing bone density.

Protocatechualdehyde (PCA) is the main degradation product of salvianolic acid B and has many activities, such as anti-inflammatory and antibacterial properties [9]. In vivo, the prodrug PCA restrains the destruction of the femoral condylar cartilage caused by adjuvant arthritis [10]. PCA significantly improves bone physical indexes, increases bone density and the levels of bone minerals and organic matter, increases the ratio of important organs, and effectively prevents the occurrence of osteoporosis caused by prednisone acetate in the growth period of rats [11]. However, the role of PCA in osteoclasts is not clear.

In this study, RAW264.7 cells (a mouse leukemic monocyte/macrophage cell line) and bone marrow macrophages (BMMs) were used to analyze the role of PCA in osteoclasts and the underlying mechanism. PCA has important theoretical significance and clinical application value in the search for economical and effective drug monomers to treat osteoporosis.

2. Materials and Methods

2.1. Materials. RAW264.7 cells were selected from ATCC (Manassas, VA, USA). BALB/c mice were purchased from Shanghai Bioengineering Company. Phalloidin was obtained from Thermo Fisher Scientific. The apoptosis kit was purchased from BD. All antibodies were acquired from Cell Signaling Technology (Beverly, MA, USA). Primers were designed by PrimerBank and synthesized by Shanghai Bioengineering Company.

2.2. Cell Culture. BMMs were acquired from both ends of cut femurs and tibias from approximately 6-week-old male BALB/c mice. The animal experiment was authorized by the Experimental Animal Ethics Review Committee of Shandong University. The marrow cavity was rinsed 3-5 times with α-MEM, and red blood cells were removed to obtain BMMs. The lysate was filtered through a 40 μm mesh filter and centrifuged to separate the cells. Samples from the mice were cultured overnight in α-MEM containing M-CSF (5 ng/ml) in a nonadherent culture plate, and then, cells suspended in the collected supernatant were cultured with M-CSF (30 ng/ml) for 3 days. The supernatant and suspended cells were discarded; the adherent cells were the BMMs.

RAW264.7 cells were cultured in complete DMEM. However, DMEM was substituted for α-MEM containing M-CSF (5 ng/ml) for 3 days. The supernatant and suspended cells were discarded; the adherent cells were the BMMs.

RAW264.7 cells were cultured in complete DMEM. However, DMEM was substituted for α-MEM containing M-CSF (5 ng/ml) for 3 days. The supernatant and suspended cells were discarded; the adherent cells were the BMMs.

RAW264.7 cells were cultured in complete DMEM. However, DMEM was substituted for α-MEM containing M-CSF (5 ng/ml) for 3 days. The supernatant and suspended cells were discarded; the adherent cells were the BMMs.

RAW264.7 cells were cultured in complete DMEM. However, DMEM was substituted for α-MEM containing M-CSF (5 ng/ml) for 3 days. The supernatant and suspended cells were discarded; the adherent cells were the BMMs.

2.3. Cytotoxicity Assay. CCK-8 assays were used to determine the toxicity of PCA toward cells. In 96-well plates, BMMs (2 x 10^4 cells/well) and RAW264.7 cells (1 x 10^4 cells/well) were seeded in the presence of PCA (0, 1, 10, 20, 30, or 50 μg/ml) for 5–6 days. CCK-8 (10 μl/well) was added to the supernatant and incubated for 0.5–1 h, and the absorbance was assayed at 452 nm by a Multiskan Go1510 microplate reader. The ratio of the experimental group to the control group represents cell activity [12].

2.4. TRAP Staining. RAW264.7 cells (5 x 10^5 cells/well) were cultured in 48-well plates, and BMMs (2 x 10^4 cells/well) were seeded in 96-well plates. The next day, 50 ng/ml RANKL and 30 ng/ml M-CSF were added to the medium. The cells were incubated for 4 days, the cells were stained and identified according to the literature [13].

2.5. Absorption Pit Assay. We used Corning Osteo Assay Surface 24-well plates to assay absorption pits. BMMs (4 x 10^5 cells/well) and RAW264.7 cells (1 x 10^5 cells/well) were seeded in 96-well plates. The next day, 50 ng/ml RANKL and 30 ng/ml M-CSF were added to the medium. The cells were incubated for 4 days, and the cells were stained for 4–8 days. After 4–8 days, a 10% bleach solution was used to wash the cells. A light microscope (Olympus) captured images of the absorption pits, and Image software quantified the image [14].

2.6. Immunofluorescence Staining of the F-Actin Ring. BMMs (3 x 10^5 cells/well) were seeded in 24-well plates, and a series of PCA, M-CSF (30 ng/ml), and RANKL (50 ng/ml) were added to the medium. The cells were incubated for 4 days, and phalloidin was used to stain the cells after fixation and permeabilization. A fluorescence microscope was used to capture fluorescence images.

2.7. Flow Cytometry Analysis. RAW264.7 cells (5 x 10^5 cells/well) were seeded in 6-well plates and cultured with a series of PCA and 50 ng/ml RANKL. After 3–4 days, the apoptosis kit was used to stain the cells. Cell apoptosis was assessed using flow cytometry.

### Table 1: The conditions and primer sequences used for RT-PCR.

| Target genes | Primer sequences | Tm | Size |
|--------------|------------------|----|------|
| GAPDH        | F: AGGTCGTTGTTGAACGGATTGTG | 95 | 60 |
|              | R: GGSSCGTTGATGGCAAAC |    |      |
| CTSK         | F: CTCGGTGTTAATTTGGGAGA | 60 | 164 |
|              | R: TCGAGAGGGAGGTATTCTGAGT |    |      |
| NFATc1       | F: GAGAGTCCGAGAATCAGATG | 60 | 102 |
|              | R: TTGCAGCTAGAAGTACGTTCT |    |      |
| C-FOS        | F: GGGTTTCTCAAGCGCGACTA | 60 | 165 |
|              | R: TGGCAGCTAGAGCCGACAGAT |    |      |
| MMP-9        | F: GCAGAGCATACTTGTACGG | 60 | 229 |
|              | R: TGATGTATGATGTTCCACCTTG |    |      |
| DC-Stamp     | F: GGGGACTTATGTTTCCACG | 60 | 72  |
|              | R: ACAAGCAACAGCTCCCAAT |    |      |
Figure 1: Continued.
2.8. RT-qPCR. RAW264.7 cells were seeded in 24-well plates (5 × 10⁴ cells/well). The next day, the cells were pretreated with a series of PCA concentrations for 60 min before adding 50 ng/ml RANKL. After 5–6 days, the cells were collected. PCR was performed as previously described [15]. Primers were listed in Table 1.

2.9. Western Blot Analysis. RAW264.7 cells (2.5 × 10⁶ cells/m) were plated in 6-well plates and then pretreated with PCA (1, 2.5, or 5 μg/ml) for 2 h before the addition of RANKL (50 ng/ml) and incubation for 10 min. Western blots were performed as previously described [11]. The levels of p-p38/p38, p-ERK/ERK, p-JNK/JNK, and p-p65/p65 are shown in histograms.

2.10. Statistical Analysis. The results are presented as means ± standard errors. Each experiment was repeated more than three times. SPSS19.0 software was used to analyze differences. P < 0.05 was defined as a statistically significant difference.

3. Results

3.1. PCA Attenuates Osteoclast Differentiation Induced by RANKL. The potential cytotoxicity of PCA toward RAW264.7 cells (Figure 1(a)) and BMMs (Figure 1(b)) was evaluated using CCK-8 assays. Based on the results, the highest concentration of PCA (5 μg/ml) has no effect on cell activity. BMMs and RAW264.7 cells were successfully induced to differentiate into osteoclasts by RANKL. The osteoclasts were large and full, with vacuoles forming in the middle.
Figure 2: Continued.
additional nuclear accumulation throughout the cells. However, when PCA was present, the size of the osteoclasts decreased, the vacuoles disappeared, and the number of surrounding nuclei decreased. Furthermore, we used TRAP to stain osteoclasts. The test results indicated that PCA prevented osteoclastic differentiation not only in BMMs but also in RAW264.7 cells (Figures 1(c)–1(f)). Thus, PCA attenuates the generation of osteoclasts.

We added 5 μg/ml PCA to the medium and induced BMMs to differentiate in three periods to determine the stage of osteoclastogenesis at which PCA exerted its effect. Osteoclast formation was markedly inhibited by PCA in the earlier period (Figures 1(g) and 1(h)), whereas the inhibitory effect of PCA decreased in the later period. These data suggested that PCA suppresses osteoclast formation mainly in the earlier period of RANKL-induced differentiation.

3.2. PCA Decreases the RANKL-Induced Formation of Absorption Pits. The absorption of osteoclasts induced by RANKL was detected. The group stimulated with RANKL formed obvious bone absorption pits, but the number and area of absorption pits decreased in the presence of PCA (Figure 2). Therefore, PCA inhibits the function of osteoclasts.

3.3. PCA Suppresses the Size of F-Actin Rings and Does Not Affect Apoptosis. The size of the F-actin ring was measured, and PCA reduced the length of the F-actin rings (Figures 3(a) and 3(b)). However, the flow cytometry analysis showed that PCA did not affect the ratio of apoptotic cells (Figures 3(c) and 3(d)). These data suggested that the inhibitory effect of PCA is not attributable to apoptosis.

3.4. PCA Attenuates the mRNA Expression of RANKL-Induced Osteoclastic Markers. The RT-qPCR results showed the mRNA levels of factors produced by RANKL-stimulated osteoclasts. The RANKL-induced group exhibited substantially increased expression of these mRNAs (Figure 4). However, PCA significantly reduced the mRNA levels of these related factors.

3.5. PCA Suppresses the Activation of the MAPK Pathway. The MAPK signaling pathway exerts an irreplaceable effect on the generation of osteoclasts. Primary members of this signaling pathway are ERK, JNK, and p38. Phosphorylation of these proteins is the main indicator of activation. We measured the levels of these proteins produced during the formation of osteoclasts in cells treated with or without PCA. The RANKL-induced group exhibited substantially increased phosphorylation of these proteins. However, the changes were inhibited by PCA (Figure 5).

3.6. PCA Prevents RANKL-Induced NF-κB Activation. The change in p65 expression was examined. We measured the levels of p65 phosphorylation during RANKL-stimulated
differentiation of cells treated with or without PCA. As shown in Figure 6, the RANKL-stimulated group exhibited increased p65 phosphorylation. However, when PCA was present, the level of p65 phosphorylation was decreased. These results indicate that PCA prevents NF-κB activation induced by RANKL.

4. Discussion

Osteoclasts are derived from promonocytes in bone marrow hematopoietic stem cells and are mainly present in the periosteum. Osteoclasts are the only cells with bone absorption functions, initiating the process of bone remodeling and
clearing old bone matrix [16]. Therefore, decreasing osteoclast differentiation or absorption may be an effective method to treat this type of pathological bone disease. This study was the first to show that PCA significantly inhibited the formation and function of RANKL-induced osteoclasts. In addition, PCA effectively inhibited the expression of osteoclast-associated marker genes stimulated by RANKL. Mechanistically, PCA suppressed RANKL-induced activation of the MAPK and NF-κB signaling pathways.

We used two types of osteoclast progenitors (BMMs and RAW264.7 cells) to study the roles of PCA in the induction and absorption function of osteoclasts [17]. Through the research, we discovered that RAW264.7 cells only proliferated in the absence of stimulation, and the proliferation of BMMs only gradually decreased. However, when stimulated with RANKL, these cells all differentiated into osteoclasts and showed absorption functions. This result is consistent with the literature [13, 14]. Furthermore, this effect was inhibited by PCA. These actions were neither related to the cytotoxic effects of PCA nor a cause of apoptosis. Therefore, we further examined the mechanism of PCA in osteoclasts.

A series of iconic factors are produced in the course of differentiation from precursor cells to mature osteoclasts and can be used as markers of osteoclasts and their differentiation stages. Cathepsin K (CTSK) is an amino acid protease expressed by osteoclasts. CTSK stimulates the expression of TRAP on osteoclasts in vitro; thus, CTSK is an important factor for determining osteoclast function [18]. The recombinant nuclear factor of activated T-cells, cytoplasmic 1(NFATc1) is the most important factor associated with NF-κB in the incipient stage of osteoclast formation. 

In vitro experiments confirmed that stem cells lacking
**Figure 5:** PCA suppresses the activation of the MAPK pathway. (a) Western blots showing protein levels. (b) The relative protein levels were compared with those in the group treated with RANKL alone. *P < 0.01 and #P < 0.05 compared with the RANKL group.

**Figure 6:** PCA prevents RANKL-induced NF-κB activation. (a) Western blots showing the levels of p-p65 and p65. (b) The protein levels were compared with those in the RANKL group. *P < 0.01 and #P < 0.05 compared with the group treated with RANKL alone.
NFATc1 fail to differentiate into osteoclasts, but ectopic NFATc1 expression in the absence of RANKL also enables BMMs to differentiate into osteoclasts [19]. These results all suggest the importance of NFATc1. Matrix metalloproteinase (MMP-9), which is abundant in osteoclasts, is an important protease that stimulates bone absorption. Specifically, MMP-9 plays a crucial function in the active transcription of osteoclastogenic genes via the cleavage of the N-terminal tail of H3 under tight epigenetic regulation [20]. Dendritic cell-specific transmembrane protein (DC-STAMP), an important molecule involved in the fusion of mononuclear cells into osteoclasts, improves the absorption function of osteoclasts [21]. Cellular oncogene FOS (C-FOS) is a proto-oncogene associated with the development of osteosarcoma. During osteoclast differentiation, C-FOS is an indispensable downstream regulatory factor of RANKL, which accelerates the formation of osteoclasts by activating the downstream factor NFATc1 [22]. In the present study, PCA reduced the mRNA levels of these factors. Therefore, PCA may inhibit the formation of osteoclasts by downregulating the expression of these genes. However, these genes are downstream of the signaling pathway, and the mechanism by which PCA modulates these downstream genes remains unclear. Therefore, we detected the levels of proteins in the MAPK and NF-κB signaling pathways.

MAPK is an important signaling pathway involved in osteoclast differentiation [23]. This pathway mainly activates and regulates key downstream regulatory molecules associated with the formation of osteoclasts, including C-FOS and NFATc1 [24], and ultimately stimulates the differentiation of osteoclasts. The ERK, JNK, and p38 subfamilies are the main MAPK subfamilies. The binding of RANKL to RANK activates ERK through a series of reactions. ERK regulates the transcription of C-FOS after translocation to the nucleus, ultimately transforming mature macrophages into precursor osteoclasts [25]. Phosphorylated JNK activates AP-1 to promote the expression of MMP and ALP genes and stimulates the differentiation, survival, fusion, activation, and maturation of osteoclasts [26]. After the binding of RANKL to RANK, MEK6 phosphorylation is promoted and p38 is activated. Activated p38 is transferred from the cytoplasm to the nucleus, phosphorylating the transcription factor MITF and other proteins, ultimately promoting osteoclast differentiation [27]. In our study, PCA reduced the phosphorylation of ERK, JNK, and p38 in RAW264.7 cells treated with RANKL. The downregulation of MAPK expression induced by PCA was consistent with previously described results [28]. These results suggest that PCA may affect the fusion of precursor cells into osteoclasts by activating MAPK to suppress the expression of downstream factors.

NF-κB signaling is another indispensable pathway in osteoclast induction [29]. The trimer of RANK-RANKL-TRAF6 activates NF-κB. Then, NF-κB separates from I-κB and is quickly transported into the nucleus, binding to the promoters of the corresponding target genes and regulating osteoclast differentiation, maturation, and apoptosis [30, 31]. In the present study, PCA reduced the level of phosphorylated p65 in RANKL-induced osteoclasts. PCA suppressed RANKL-mediated osteoclast formation by inhibiting NF-κB activity. PCA possibly inhibits the transcription of NFATc1 by restraining the phosphorylation of NF-κB p65, thereby affecting the expression of downstream genes.

PCA is a water-soluble component of SM. SM and its other active ingredients are known to possess antiosteoporosis properties. Tanshinone is one of the most much-studied active components at present. Published studies have shown that tanshinone inhibits osteoclast activation and reduces bone absorption by destroying F-actin rings [32]. Cryptotanshinone also inhibits the formation of osteoclasts [33]. In our study, PCA reduced the number of TRAP-positive osteoclasts and the area of absorption pits, which proved that PCA inhibited the maturation and function of osteoclasts, suggesting that PCA has the potential to prevent bone loss and treat osteoporosis. Based on the findings of the present study, PCA exerts a synergistic effect with the abovementioned components of SM. This result further suggests that SM may also be an antiosteoporotic treatment that inhibits the maturation and function of osteoclasts.

Although some results were reported in our study, many other issues remain to be further explored. For example, how does PCA suppress the activation of MAPK and NF-κB? Does PCA bind to cognate receptors on the cell surface of precursor cells and subsequently inhibit cellular signaling pathways that lead to NF-κB and MAPK activation, or does PCA freely enter cells and directly inhibit NF-κB and MAPK activation? Other questions include the effectiveness of PCA in vivo and its pharmacokinetics, which all require further study.

In conclusion, our research shows that PCA suppresses osteoclast differentiation by inhibiting MAPK and NF-κB activation. Therefore, PCA potentially represents a cost-effective and alternative medicine for osteoporosis.

Data Availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

This study was funded by the National Key Research and Development Program of China (SQ2017YFSF080004), Natural Science Foundation of Shandong Province (ZR2017PH035), and Shandong Traditional Chinese Medicine Science and Technology Development Project (2019-0219).

References

[1] P. D. Miller, "Management of severe osteoporosis," Expert Opinion on Pharmacotherapy, vol. 17, no. 4, pp. 473–488, 2016.

[2] M. Tsukasaki and H. Takayanagi, "Osteoimmunology: evolving concepts in bone-immune interactions in health and
Disease," *Nature Reviews Immunology.*, vol. 19, no. 10, pp. 626–642, 2019.

3. P. Q. Meng and Y. X. Guo, "Bilateral maxillary bisphosphonate-related osteonecrosis of the jaw: a case report," *Beijing Da Xue Xue Bao Yi Xue Ban*, vol. 49, no. 6, pp. 1098–1102, 2017.

4. J. Liu, H. X. Zhang, X. X. Lu, J. J. Hu, and L. F. Deng, "Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: sensitivity and trim and fill studies," *Genetic Testing and Molecular Biomarkers*, vol. 18, no. 2, pp. 117–122, 2014.

5. Y. Liu, J. P. Liu, and Y. Xia, "Chinese herbal medicines for treating osteoporosis," *Cochrane Database of Systematic Reviews*, vol. 3, 2014.

6. B. Park, H. S. Song, J. E. Kwon et al., "Effects of Salvia miltiorrhiza extract with supplemental liquefied calcium on osteoporosis in calcium-deficient ovarectomized mice," *BMC Complementary and Alternative Medicine*, vol. 17, no. 1, p. 545, 2017.

7. B. Miao, J. Wang, Y. Zhu, C. Yue, and M. Chen, "Experimental study on effect of Salvia miltiorrhiza on alveolar bone metabolism and variation in bone mass in diabetic rats," *Zhongguo Zhong Yao Za Zhi*, vol. 37, no. 11, pp. 1659–1662, 2012.

8. L. Cui, T. Li, Y. Liu et al., "Salvianolic acid B prevents bone loss in prednisone-treated rats through stimulation of osteogenesis and bone marrow angiogenesis," *PLoS One*, vol. 7, no. 4, article e34647, 2012.

9. S. Li, Y. Yu, J. Chen, B. Guo, and L. Yang, "Evaluation of the antibacterial effects and mechanism of action of protocatechualdehyde against Ratlstonia solanacearum," *Molecules*, vol. 21, no. 6, p. 754, 2016.

10. K. Watanebe, H. Hayashi, and Y. Morii, "Effect of a benzyldiene derivative, a novel antirheumatic agent, on IL-1 production," *Pharmacological Research*, vol. 28, no. 1, pp. 59–72, 1993.

11. Y. X. Ding, C. Y. Chang, W. Hu, and Y. J. Zhou, "Protocatechualdehyde prevention and treatment of osteoporosis in growing rats induced by prednisone acetate," *Hebei Medical Journal.*, vol. 34, no. 8, pp. 1125–1127, 2012.

12. X. Z. Zeng, L. G. He, S. Wang et al., "Aconine inhibits RANKL-induced osteoclast differentiation in RAW264.7 cells by suppressing NF-κB and NFATc1 activation and DC-STAMP expression," *Acta Pharmacologica Sinica*, vol. 37, no. 2, pp. 255–263, 2016.

13. F. Chen, L. Xie, R. Kang et al., "Gentiopicroside inhibits RANKL-induced osteoclastogenesis by regulating NF-κB and JNK signaling pathways," *Biomedicine & Pharmacotherapy*, vol. 100, pp. 142–146, 2018.

14. M. Sapkota, L. Li, S. W. Kim, and Y. Soh, "Thymol inhibits RANKL-induced osteoclastogenesis in RAW264.7 and BMM cells and LPS-induced bone loss in mice," *Food and Chemical Toxicology*, vol. 120, pp. 418–429, 2018.

15. Y. P. Zeng, C. Yang, Y. Li et al., "Aspirin inhibits osteoclastogenesis by suppressing the activation of NF-κB and MAPKs in RANKL-induced RAW264.7 cells," *Molecular Medicine Reports*, vol. 14, no. 3, pp. 1957–1962, 2016.

16. E. Kylmaoja, M. Nakamura, and J. Tuukkanen, "Osteoclasts and remodeling based bone formation," *Current Stem Cell Research & Therapy*, vol. 11, no. 8, pp. 626–633, 2016.

17. D. H. Yang and M. Y. Yang, "The role of macrophage in the pathogenesis of osteoporosis," *International Journal of Molecular Sciences*, vol. 20, no. 9, p. 2093, 2019.

18. T. Goto, T. Yamaza, and T. Tanaka, "Cathepsins in the osteoclast," *Journal of Electron Microscopy*, vol. 52, no. 6, pp. 551–558, 2003.

19. S. H. Moon, S. W. Choi, and S. H. Kim, "_In vitro_ anti-osteoclastogenic activity of p38 inhibitor doramapimod via inhibiting migration of pre-osteoclasts and NFATc1 activity," *Journal of Pharmacological Sciences*, vol. 129, no. 3, pp. 135–142, 2015.

20. Y. J. Kim, J. M. Kim, H. Lee et al., "Tetracycline analogs inhibit osteoclast differentiation by suppressing MMP-9-mediated histone H3 cleavage," *International Journal of Molecular Sciences*, vol. 20, no. 16, pp. 4038–4052, 2019.

21. Y.-H. Chiu and C. T. Ritchlin, "DC-STAMP: a key regulator in osteoclast differentiation," *Journal of Cellular Physiology*, vol. 231, no. 11, pp. 2402–2407, 2016.

22. B. C. Jeong, J. H. Kim, K. Kim, S. Seong, and N. Kim, "ATF3 modulates calcium signaling in osteoclast differentiation and activity by associating with c-Fos and NFATc1 proteins," *Bone*, vol. 95, pp. 33–40, 2017.

23. P. J. Marie, "Signaling pathways affecting skeletal health," *Current Osteoporosis Reports*, vol. 10, no. 3, pp. 190–198, 2012.

24. D. Q. Chen, J. Q. Huang, X. J. Yi, and D. J. Zhang, "The role of c-fos in the production of follicle-stimulating hormone and the related signal transduction pathways," *Sheng Li Ke Xue Jin Zhan*, vol. 46, no. 6, pp. 408–414, 2015.

25. J. Meng, J. Hong, C. Zhao et al., "Low-intensity pulsed ultrasound inhibits RANKL-induced osteoclast formation via modulating ERK-c-Fos-NFATc1 signaling cascades," *American Journal of Translational Research*, vol. 10, no. 9, pp. 2901–2910, 2018.

26. M. Yu, X. Chen, C. Lv et al., "Curcumin suppresses RANKL-induced osteoclast formation by attenuating the JNK signaling pathway," *Biochemical and Biophysical Research Communications*, vol. 447, no. 2, pp. 364–370, 2014.

27. E. Rodriguez-Carballo, B. Gámez, and F. Ventura, "p38 MAPK signaling in osteoblast differentiation," *Frontiers in Cell and Development Biology*, vol. 4, p. 40, 2016.

28. C. Y. Moon, C. R. Ku, Y. H. Cho, and E. J. Lee, "Protocatechuic aldehyde inhibits migration and proliferation of vascular smooth muscle cells and intravascular thrombosis," *Biochemical and Biophysical Research Communications*, vol. 423, no. 1, pp. 116–121, 2012.

29. G. Swarnkar and Y. Abu-Amer, "Regulation of NF-κB signaling in osteoclasts and myeloid progenitors," *Methods in Molecular Biology*, vol. 1280, pp. 527–542, 2015.

30. H. Liu, S. Tamashiro, S. Baritaki et al., "TRAF6 activation in multiple myeloma: a potential therapeutic target," *Clinical Lymphoma, Myeloma & Leukemia*, vol. 12, no. 3, pp. 155–163, 2012.

31. I. von Metzler, H. Krebbel, U. Kuckelkorn et al., "Curcumin diminishes human osteoclastogenesis by inhibition of the signalsome-associated I kappaB kinase," *Journal of Cancer Research and Clinical Oncology*, vol. 135, no. 2, pp. 173–179, 2009.

32. S. Y. Lee, D. Y. Choi, and E. R. Woo, "Inhibition of osteoclast differentiation by tanshinones from the root of Salvia miltiorrhiza bunge," *Archives of Pharmacal Research*, vol. 28, no. 8, pp. 909–913, 2005.

33. W. Wang, M. Huang, Y. Hui, P. Yuan, X. Guo, and K. Wang, "Cryptotanshinone inhibits RANKL-induced osteoclastogenesis by regulating ERK and NF-κB signaling pathways," *Journal of Cellular Biochemistry*, vol. 120, no. 5, pp. 7333–7340, 2019.